Drug Profile
Tetomilast
Alternative Names: OPC-6535Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Class Anti-inflammatories; Anti-ischaemics; Carboxylic acids; Pyridines; Small molecules; Thiazoles
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
- Discontinued Crohn's disease; Heart failure; Reperfusion injury; Ulcerative colitis
Most Recent Events
- 09 Sep 2015 Phase-II development is ongoing for Chronic obstructive pulmonary disease in Japan, US and Asia
- 07 Aug 2015 Otsuka terminates phase II trial in Chronic obstructive pulmonary disorders in USA (NCT00874497)
- 01 Apr 2014 Otsuka Pharmaceutical completes a phase II in Chronic obstructive pulmonary disease in Japan, China, and South Korea (NCT00917150)